期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

抗肿瘤新生血管药物在淋巴瘤中的应用 被引量：2

下载PDF
导出
作者 朱军 张晨
机构地区 北京肿瘤医院暨北京市肿瘤防治研究所
出处 《实用临床医药杂志》 CAS 2008年第6期5-8,共4页 Journal of Clinical Medicine in Practice
基金 国家自然科学基金资助项目(30772501)
关键词 恶性淋巴瘤 肿瘤血管 贝伐单抗 内皮抑素
分类号 R730.5 [医药卫生—肿瘤]
  • 相关文献

参考文献14

  • 1Moliea S, Vitelli G, Levato D, et al. Serum angiogenin is not elevated in patients with early B-cell chronic lymphocytic leukemia but is prognostic factor for disease progression[J ]. Eur J Haematol, 2004, 73: 36.
  • 2Gu J, Gadonski G, Wang J, et al. Exercise increases endostatin in circulation of health volunteers[J ]. BMC Physiol, 2004, 4: 2.
  • 3Shichiri M, Hirata Y. Antiangiogenesis signals by endostatin [J].FASEB J, 2001, 15: 1044.
  • 4Kini A R. Angiogenesis in leukemia and lymphoma[J]. Cancer Treat Res, 2004, 121 : 221.
  • 5Wang E S, Teruya-Feldstein J, Wu Y, et al. Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo[J]. Blood, 2004, 104: 2893.
  • 6Zhao W L, Mourah S, Mounier N, et al. Vascular endothelial growth factor-A is expressed both on lymphoma calls and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression[J ]. Lab Invest, 2004, 84: 1512.
  • 7Aoki Y, Tosato G. Role of vascular endothelial growth factor/vascular permeability factor in the pathogenesis of Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphomas[J]. Blood, 1999, 94: 4247.
  • 8Petri Bono, Lasse Teerenhovi, et al. Elevated Serum Endostatin Is Associated with Poor Outcome in Patients with Non -Hodgkin Lymphoma[.] ]. CANCER, 2003, 97 : 2767.
  • 9Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal[J]. N Engl J Med, 2004, 350: 2335.
  • 10Hurwitz H, Fehrenbacher L, Novomy W, et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer[J].N Eengl J Med, 2004, 350: 2335.

二级参考文献56

  • 1杨林,王金万,汤仲明,刘秀文,黄镜,李树婷,董英,张和平,薛岚,储大同,孙燕.重组人血管内皮抑制素Ⅰ期临床研究[J].中国新药杂志,2004,13(6):548-553. 被引量：154
  • 2周清华,孙燕.加强我国肺癌分子靶向治疗基础和临床研究[J].中国肺癌杂志,2004,7(4):267-269. 被引量：51
  • 3杨林,王金万,崔成旭,黄镜,张和平,李树亭,孙燕.重组人血管内皮抑制素YH-16联合用药治疗晚期非小细胞肺癌的多中心Ⅱ期临床试验[J].中国新药杂志,2005,14(2):204-207. 被引量：116
  • 4Folkman J. Role of angiogenesis in tumor growth and metastasis,Semin Oncol,2002,29(6 Suppl 16) : 15-18.
  • 5Shichiri M, Hirata Y, Antlangiogenesis signals by endostatin.FASEB J, 2001, 15(6): 1044-1053.
  • 6Huang X, Wong MK, Zhao Q, et al, Soluble recombinant endostatin purified from Escherichia coli: antiangiogenic activity and antitumor effect. Cancer Res, 2001, 61(2) :478-481.
  • 7Kreuger J, Matsumoto T, Vanwildemeersch M, et al. Role of heparan sulfate domain organization in endostatin inhibition of endothelial cell function. EMBO J,2002, 21(23) :6303-6311.
  • 8Zatterstrom UK, Felbor U, Fukai N, et al. Collagen XVIII/endostatin structure and functional role in angiogenesis. Cell Struct Funct, 2000, 25(2):97-101.
  • 9Ergun S, Kilic N, Wurmbach JH, et al. Endostatin inhibits angiogenesis by stabilization of newly formed endothelial tubes. Angiogenesis, 2001, 4(3) : 193-206.
  • 10Karumanchi SA, Jha V, Ramchandran R, et al. Cell surface glypicans are low-affinity endostatin receptors. Mol Cell, 2001, 7(4):811-822.

共引文献642

同被引文献27

  • 1王金万,孙燕,刘永煜,于起涛,张沂平,李凯,朱允中,周清华,侯梅,管忠震,李维廉,庄武,王东林,梁后杰,秦凤展,卢辉山,刘晓晴,孙红,张燕军,王杰军,罗素霞,杨瑞合,涂远荣,王秀问,宋恕平,周静敏,游丽芬,王竞,姚晨.重组人血管内皮抑素联合NP方案治疗晚期NSCLC随机、双盲、对照、多中心Ⅲ期临床研究[J].中国肺癌杂志,2005,8(4):283-290. 被引量：626
  • 2刘梅梅,隋丽华,李佩玲,程丽,李文辉.内皮抑素抑制SKOV_3细胞生长及其在裸鼠皮下移植瘤中的作用机制[J].肿瘤,2006,26(10):905-909. 被引量：2
  • 3HAN X, KILFOY B, ZHENG T, et al. Lymphoma survival patterns by WHO subtype in the United States, 1973-2003 [ J ]. Cancer Causes Control, 2008,19 ( 8 ) : 841-858.
  • 4THOMAS DA, FADEL S,O' BRIEN S,et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastie leukemia [J]. Cancer, 2006,106(7) :1569-1580.
  • 5RUAN J, HYJEK E, KERMANI P,et al. Magnitude of stromal hemangiogenesis correlates with histologic subtype of non- Hodgkin' s lymphoma[ J]. Clin Cancer Res,2006,12 ( 19 ) :5622- 5631.
  • 6BERTOLINI F, FUSETTI L, MANCUSO P, et al. Endostatin, an antiangiogeneic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma [ J ]. Blood,2000,96 ( 1 ) : 282- 287.
  • 7KELLAND L R. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development [ J]. Eur J Cancer, 2004, 40(6) :827-836.
  • 8KELLAND L R, SMITH V, VALENTI M, et al. Preclinical antitumor activity and pharmacodyuamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer [ J]. Clin Cancer Res, 2001,7 ( 11 ) :3544-3550.
  • 9KELLAND L R, SHARP S Y, ROGERS P M, et al. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90 [ J ]. J Natl Cancer lnst, 1999, 91 (22) : 1940-1949.
  • 10WORKMAN P, BALMAIN A, HICKMAN JA, et al. UKCCCR Guidelines for the welfare of animals in experimental neoplasia ( second edition) [ J ]. Cancer Metastasis Rev, 1998,77 ( 1 ) : 1-10.

引证文献2

二级引证文献18

实用临床医药杂志
2008年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部